Prevalence of Mycobacterium lentiflavum in cystic fibrosis patients, France

BMC Pulmonary Medicine

Michel Drancourt⁴  Elsa Prudent¹  Marielle Bedotto¹  Nathalie Stremler le Bel³  Carine Gomez²  Martine Reynaud-Gaubert²  Jean-Christophe Dubus³  Michael Phelippeau¹ 

[1] Aix Marseille Université, URMITE, UMR CNRS 7278, IRD 198, INSERM 1095. Faculté de Médecine, Marseille 13005, France;Centre de Ressource et de Compétences de la Mucoviscidose (CRCM) adulte; équipe de Transplantation pulmonaire, CHU Hôpital Nord, URMITE - CNRS-UMR 6236 Aix-Marseille Université, Marseille, France;Centre de Ressource et de Compétences de la Mucoviscidose (CRCM) pédiatrique CHU Hôpital la Timone, Marseille, France;Unité de recherche sur les maladies infectieuses et tropicales émergentes, Faculté de Médecine, 27 Bd jean Moulin, Marseille, 13385, cedex 5, France

关键词: smpB;    rpoB;    Cystic fibrosis;    Mycobacterium lentiflavum;   

Others  :  1231056
DOI  :  10.1186/s12890-015-0123-y

 received in 2015-05-18, accepted in 2015-10-12,  发布年份 2015

【 摘 要 】

Background

Mycobacterium lentiflavum is rarely isolated in respiratory tract samples from cystic fibrosis patients. We herein describe an unusually high prevalence of M. lentiflavum in such patients.

Methods

M. lentiflavum, isolated from the respiratory tract of cystic fibrosis patients, was identified using both rpoB partial sequencing and detected directly in the sputum by using real-time PCR targeting the smpB gene.

Results

M. lentiflavum emerged as the third most prevalent nontuberculous mycobacterial species isolated in cystic fibrosis patients in Marseille, France. Six such patients were all male, and two of them may have fulfilled the American Thoracic Society clinical and microbiological criteria for M. lentiflavum potential lung infection.

Conclusions

M. lentiflavum was the third most common mycobacteria isolated in cystic fibrosis patients, particularly in six male patients. M. lentiflavum outbreaks are emerging particularly in cystic fibrosis patients.

【 授权许可】

   
2015 Phelippeau et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Springer B, Wu WK, Bodmer T, Haase G, Pfyffer GE, Kroppenstedt RM et al.. Isolation an characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov. J Clin Microbiol. 1996; 34:1100-7.
• [2]Haase G, Kentrup H, Skopnik H, Springer B, Böttger EC. Mycobacterium lentiflavum: an etiologic agent of cervical lymphadenitis. Clin Infect Dis. 1997; 25:1245-6.
• [3]Cabria F, Torres MV, Garcia Cia JI, Dominguez-Guarrido MN, Esteban J, Jimenez MS. Cervical lymphadenitis caused by Mycobacterium lentiflavum. Pediatr Infect Dis J. 2002; 21:574-5.
• [4]Asiimwe B, Bagyenzi GB, Ssengooba W, Mumbowa F, Mboowa G, Wajja A et al.. Species and genotypic diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis in rural Uganda. BMC Infect D. 2013; 13:88-94. BioMed Central Full Text
• [5]Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, Ravilly S et al.. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol. 2009; 47:4124-8.
• [6]Seddon P, Fidler K, Raman S, Wyatt H, Ruiz G, Elston C et al.. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom. Emerg Infect D. 2009; 19:1128-30.
• [7]Olivier K, Weber DJ, Wallace RJ, Faiz AR, Lee JH, Zhang Y et al.. Nontuberculous mycobacteria I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003; 167:828-34.
• [8]Satana D, Erkose-Genc G, Tamay Z, Uzun M, Guler N, Erturan Z. Prevalence and drug resistance of mycobacteria in Turkish cystic fibrosis patients. Ann Clin Microbiol Antimicrob. 2014; 13:28. BioMed Central Full Text
• [9]Marshall H, Carter R, Torbey MJ, Minion S, Tolson C, Sidjabat HE et al.. Mycobacterium lentiflavum in drinking water supplies, Australia. Emerg Infect Dis. 2011; 17:395-402.
• [10]Cock PJ, Chilton JM, Grüning B, Johnson JE, Soranzo N. NCBI BLAST+ integrated into Galaxy. Gigascience. 2015; 4:39. BioMed Central Full Text
• [11]Adékambi T, Colson P, Drancourt M. rpoB-based identification of nonpigmented and late-pigmented rapidly growing mycobacteria. J Clin Microbiol. 2003; 41:5699-708.
• [12]Griffith D, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F et al.. An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175:367-416.
• [13]Pierre-Audigier C, Sermet-Gaudelus I, Le Bourgeois M, Offredo C, Vu-Thien H, Fauroux B et al.. Age-related prevalence and distribution of nontuberculous species among patients with cystic fibrosis. J Clin Microbiol. 2005; 43:3467-70.
• [14]Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T et al.. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013; 381:1551-60.
• [15]Miller K, Harrington SM, Procop GW. Acid-fast smear and histopathology results provide guidance for the appropriate use of broad-range polymerase chain reaction and sequencing for mycobacteria. Arch Pathol Lab Med. 2015. [Epub ahead of print].
• [16]Nagata N, Honda M, Kobayakawa M, Maeda S, Sakurai T, Akiyama J et al.. Mycobacterium lentiflavum ileitis using aspirated intestinal fluid during endoscopy in HIV-infected patient. Dig Endosc. 2011; 23:271-2.
• [17]Ibanez R, Serrano-Heranz R, Jimenez-Palop M, Roman C, Corteguera M, Jimenez S. Disseminated infection caused by slow-growing Mycobacterium lentiflavum. Eur J Clin Microbiol Infect Dis. 2002; 21:691-2.
• [18]Thomas G, Hraiech S, Dizier S, Weiller PJ, Ene N, Serratrice J et al.. Disseminated Mycobacterium lentiflavum in a heart-transplanted man responsible for haemophagocyticlymphohistocytosis. J Clin Microbiol. 2014; 52:3121-3.
• [19]Levy I, Grisaru-Soen G, Lerner-Geva L, Kerem E, Blau H, Bentur L et al.. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis. 2008; 14:378-84.
• [20]Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K et al.. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest. 2014; 121:3554-63.